Petroula Proitsi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3618351/publications.pdf

Version: 2024-02-01

70 papers	14,629 citations	117625 34 h-index	91884 69 g-index
93 all docs	93 docs citations	93 times ranked	18847 citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
3	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
4	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. Nature Genetics, 2019, 51, 404-413.	21.4	1,625
5	Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Human Molecular Genetics, 2009, 18, 472-481.	2.9	512
6	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimerâ€™s disease. Nature Genetics, 2021, 53, 1276-1282.	21.4	430
7	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353
8	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
9	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 271-278.	3.1	256
10	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
11	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
12	Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Medicine, 2015, 12, e1001841.	8.4	153
13	Association of blood lipids with Alzheimer's disease: AÂcomprehensiveÂlipidomics analysis. Alzheimer's and Dementia, 2017, 13, 140-151.	0.8	144
14	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease, 2012, 30, 685-710.	2.6	141
15	Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e64971.	2.5	122
16	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nature Communications, 2017, 8, 910.	12.8	118
17	Risk of developing dementia in people with diabetes and mild cognitive impairment. British Journal of Psychiatry, 2010, 196, 36-40.	2.8	115
18	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	3.1	115

#	Article	IF	Citations
19	Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. Neurobiology of Aging, 2014, 35, 1850-1854.	3.1	114
20	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	2.6	91
21	Effect of APOE Îµ4 Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	2.6	82
22	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	8.4	75
23	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	2.6	72
24	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
25	Smell identification function as a severity and progression marker in Alzheimer's disease. International Psychogeriatrics, 2013, 25, 1157-1166.	1.0	68
26	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
27	Complement activation as a biomarker for Alzheimer's disease. Immunobiology, 2012, 217, 204-215.	1.9	59
28	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Clinical Infectious Diseases, 2013, 56, 1695-1703.	5.8	58
29	Association of a Locus in theCAMTA1Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
30	Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiology of Aging, 2014, 35, 279-290.	3.1	56
31	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	3.1	51
32	Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiology of Aging, 2012, 33, 791-803.	3.1	49
33	Combinatorial Markers of Mild Cognitive Impairment Conversion to Alzheimer's Disease - Cytokines and MRI Measures Together Predict Disease Progression. Journal of Alzheimer's Disease, 2011, 26, 395-405.	2.6	47
34	Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiology of Aging, 2012, 33, 1849.e5-1849.e18.	3.1	43
35	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Reports, 2020, 33, 108323.	6.4	41
36	Positional Pathway Screen of wnt Signaling Genes in Schizophrenia: Association with DKK4. Biological Psychiatry, 2008, 63, 13-16.	1.3	37

#	Article	IF	Citations
37	Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimerâ€™s disease. Translational Neurodegeneration, 2020, 9, 36.	8.0	37
38	Alzheimerâ€™s disease-related dysregulation of mRNA translation causes key pathological features with ageing. Translational Psychiatry, 2020, 10, 192.	4.8	37
39	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 273.	4.8	36
40	Association between polygenic risk score of Alzheimerâ€™s disease and plasma phosphorylated tau in individuals from the Alzheimerâ€™s Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	6.2	35
41	Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
42	Pattern of Smell Identification Impairment in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 381-387.	2.6	33
43	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	2.6	30
44	Urinary metabolic phenotyping for Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 21745.	3.3	30
45	Rheumatoid arthritis and risk for Alzheimerâ€™s disease: a systematic review and meta-analysis and a Mendelian Randomization study. Scientific Reports, 2017, 7, 12861.	3.3	27
46	Lifestyle mediates the role of nutrient-sensing pathways in cognitive aging: cellular and epidemiological evidence. Communications Biology, 2020, 3, 157.	4.4	27
47	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiology of Aging, 2012, 33, 1843.e9-1843.e17.	3.1	24
48	Lipidomics comparing DCD and DBD liver allografts uncovers lysophospholipids elevated in recipients undergoing early allograft dysfunction. Scientific Reports, 2015, 5, 17737.	3.3	22
49	Lifetime cognition and late midlife blood metabolites: findings from a British birth cohort. Translational Psychiatry, 2018, 8, 203.	4.8	21
50	Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease. PLoS ONE, 2011, 6, e17298.	2.5	21
51	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
52	Circulating Metabolome and White Matter Hyperintensities in Women and Men. Circulation, 2022, 145, 1040-1052.	1.6	17
53	Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex. Neurobiology of Aging, 2020, 89, 83-88.	3.1	13
54	The deletion variant of Î±2b-adrenergic receptor is associated with decreased risk in Alzheimer's disease and mild cognitive impairment. Journal of the Neurological Sciences, 2013, 328, 19-23.	0.6	12

#	Article	IF	Citations
55	No Genetic Overlap Between Circulating Iron Levels and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 59, 85-99.	2.6	10
56	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	3.1	9
57	Metabolic correlates of late midlife cognitive outcomes: findings from the 1946 British Birth Cohort. Brain Communications, 2022, 4, fcab291.	3.3	9
58	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
59	Missense substitutions associated with behavioural disturbances in Alzheimer's disease (AD). Brain Research Bulletin, 2012, 88, 394-405.	3.0	6
60	Disentangling Independent and Mediated Causal Relationships Between Blood Metabolites, Cognitive Factors, and Alzheimerâ€™s Disease. Biological Psychiatry Global Open Science, 2022, 2, 167-179.	2.2	6
61	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 1825-1839.	2.6	5
62	A genome-wide association study of plasma phosphorylated tau181. Neurobiology of Aging, 2021, 106, 304.e1-304.e3.	3.1	5
63	Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1117-1127.	2.6	5
64	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	2.6	2
65	Disentangling the Complex Relationship Between Hypertension and Dementia. Biological Psychiatry, 2021, 89, 742-744.	1.3	1
66	Genes of the serotonergic and dopaminergic pathways and their interaction affect the expression of Behavioural and Psychological Symptoms in Dementia (BPSD).. Nature Precedings, 2009, , .	0.1	0
67	O4-05-05: Genetic influences on metabolite levels in Alzheimer's disease. , 2015, 11, P279-P280.		0
68	[F1â€“02â€“02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P174.	0.8	0
69	Association of TREM2 variants and sphingolipid levels with AD in blood and brain. Alzheimer's and Dementia, 2020, 16, e046579.	0.8	0
70	Hypertension, brain training and cognition in the healthy adults aged over 50 years: An online longitudinal study. Alzheimer's and Dementia, 2021, 17, .	0.8	0